- 2023
-
Press releases - 10.03.2023
Against Whooping Cough and Its Transmission, a New Safe and Effective Nasal Vaccine
Highly infectious and potentially life-threatening in infants, whooping cough, caused by the bacterium Bordetella pertussis, continues to circulate to a large extent throughout the world. Although the vaccines currently used protect against the onset of symptoms, they have limited durability and cannot prevent bacterial infection resulting in transmission between individuals.
-
Press releases - 07.03.2023
A New Milestone in the Development of an Effective Allergic Asthma Vaccine
To combat allergic asthma, which affects millions of people worldwide, scientists from Inserm, CNRS and Université Toulouse III-Paul Sabatier at the Infinity laboratory[1], Institut Pasteur and French company NEOVACS are developing and testing a new vaccine.
-
Press releases - 27.02.2023
Pre- and Postnatal Chlordecone Exposure Could Affect the Cognitive Development and Behavior of Children
Despite the fact that chlordecone has not been used as an insecticide in the French West Indies for 30 years now, its persistence in the environment continues to contaminate the populations.
-
Press releases - 23.02.2023
Cannabis: Insomnia Twice as Common Among Students Who Use It Every Day
In a new study, researchers from Inserm, Université de Bordeaux and Bordeaux University Hospital focused on cannabis use by students – with the knowledge that its consumption among 18-25-year-olds in France is particularly high – and tried to measure its effects on sleep.
-
Press releases - 23.02.2023
New data of efficacy of a Meningococcal B Vaccine and a Preventive Antibiotic in Reducing the Risk of Sexually Transmitted Bacterial Infections and proven efficacy of the MVA-BN Vaccine Against Mpox
Une étude menée par une équipe de recherche de l’AP-HP, Université Paris Cité, l’Inserm, Sorbonne Université en collaboration avec AIDES et Coalition PLUS démontre à la fois l’efficacité d’un vaccin contre le méningocoque B dans la réduction du risque d’infection par le gonocoque et celle de l’utilisation de l’antibiotique doxycycline comme traitement préventif contre les infections sexuellement transmissibles, lorsqu’il est pris dans les 72 h suivant un rapport sexuel.
-
Press releases - 21.02.2023
A blood factor involved in depression
Scientists from the Institut Pasteur, CNRS and Inserm have discovered that administration of the GDF11 protein, which is known to regenerate murine neural stem cells, improves cognitive abilities and reduces the depressive state in aged mice. They also demonstrated the mechanism of action of this protein in different mouse models. The scientists then investigated these results further in relation to depression, and showed that in humans, the levels of GDF11 are inversely related to depressive episodes.
-
Press releases - 20.02.2023
Obesity and Overweight: Almost One in Two French People Affected. Current Situation, Prevention and Therapeutic Solutions
Obesity is a global public health problem whose incidence continues to increase. According to the World Health Organization (WHO), the number of cases worldwide has almost tripled since 1975.
-
Press releases - 13.02.2023
Who are the first ancestors of present-day fish?
What is the origin of the ancestors of present-day fish? What species evolved from them? A 50-year-old scientific controversy revolved around the question of which group, the “bony-tongues” or the “eels”, was the oldest. A study by INRAE, the CNRS, the Pasteur Institute, Inserm and the Muséum National d’Histoire Naturelle, has just put an end to the debate by showing through genomic analysis that these fishes are in fact one and the same group, given the rather peculiar name of “Eloposteoglossocephala”.
-
Press releases - 01.02.2023
Professor Didier Samuel Appointed Chairman and Chief Executive Officer of Inserm
Appointed today in the Council of Ministers following the proposal of the Minister of Higher Education and Research and the Minister of Health and Prevention, Professor Didier Samuel becomes Chairman and Chief Executive Officer of Inserm.
-
Press releases - 26.01.2023
Cystic Fibrosis: A New Therapeutic Avenue Thanks to Research Into an Edible Mushroom
Une molécule issue d’un champignon comestible pourrait ouvrir des perspectives thérapeutiques pour des patients atteints de mucoviscidose, la maladie génétique rare la plus fréquente. Une équipe de recherche dirigée par Fabrice Lejeune, chercheur Inserm au sein du laboratoire Cancer heterogeneity, plasticity and resistance to Therapies (Inserm/ CNRS/ Université de Lille/Institut Pasteur de Lille/CHU Lille) a testé les effets de la 2,6-diaminopurine (DAP), l’un des principes actifs contenus dans le champignon Lepista flaccida, dans différents modèles expérimentaux de la maladie. Les scientifiques ont ainsi montré que cette molécule pourrait avoir un intérêt thérapeutique pour les patients atteints de mucoviscidose liée à une mutation particulière, dite mutation non-sens.